ClinicalTrials.gg
RecruitingNCT06951074Updated Apr 30, 2025

Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes

A Phase 2/3 interventional study of Insulin producing stem cells infusion in Stem Cells and Type 1 Diabetes, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 15 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Ain Shams University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
15 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University — 3 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Ain Shams University.

Planned enrollment
16th of 18
20 · median 60
Started
2025
the only one that year
Phase 2/3
5 of 20
2 open now
Registered
15th of 20
by date

Among the 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University, this one is the 16th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2/3, and was the 15th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 15 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetes Mellitus, Type 1 by Ain Shams University, or all of them as a file.
02

Study summary

Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.

Read the detailed description

Differentiation of stem cells from various sources to form insulin-producing cells (IPCS) provides a new and promising strategy to reconstitute pancreatic endocrine function. Studies recently developed a multistep differentiation technique for the differentiation of human embryonic stem cells to form pancreatic progenitors. At the end of in vitro differentiation approximately 5% of cells became insulin positive.

Mesenchymal stem cells (MSCs) can be derived from various sources. MSCs are undifferentiated cells with multilinear potential, known for their immunomodulatory and regenerative properties . The bone marrow, adipose tissue, umbilical cord, liver cells, and endometrium are among several tissues that are rich in MSCs. Of these, the bone marrow and adipose tissues offer distinct advantages in view of their availability and abundance and the extent of their documentation.

In this study the investigators aim to obtain autologous differentiated insulin producing mesenchymal stem cells (derived from adipose tissue) and their introduction in human subjects with type 1 diabetes. The current study will assess of the ability of the transplanted cells to produce insulin both in vitro and in vivo. Post- transplant glycemic control will be assessed with possible amelioration of the standard treatment of type 1 diabetes.

03

Conditions studied

  • Stem Cells
  • Type 1 Diabetes
04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes

Exclusion criteria

Exclusion Criteria:

  • patients with other diseases
  • patients with micro or macro vascular complications
  • patients with other chronic diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    group 1a IPSC transplant in portal circulation

    Insulin producing stem cells injection in portal circulation

    Biological: Insulin producing stem cells infusion

  • Experimental
    group 1b IPSC in peripheral systemic circulation

    Insulin producing stem cells injection in peripheral systemic circulation

    Biological: Insulin producing stem cells infusion

Interventions

  • BiologicalInsulin producing stem cells infusion

    1. Liposuction of the anterior abdominal subcutaneous fat layer of participant 2. Characterization and Identification of mesenchymal stem cells 3. Differentiation of mesenchymal stem cells into insulin producing stem cells 4. In vitro detection of Insulin and c-peptide in differentiated MSC (Confirmatory tests for the insulin producing cells) 5. In vitro Insulin and c-peptide release detection in differentiated MSC in response to increasing glucose concentrations Differentiated MSCs injection in human subjects 6. Followup

06

What researchers measure

Primary outcomes

  1. Insulin producing mesenchymal stem cells efficacy in insulin production in vitro

    Assessment of the percentage of mature insulin and c peptide production in insulin producing stem cells.

    Time frame: 1 year

  2. Insulin producing mesenchymal stem cells efficacy in insulin production in vitro

    Assestment of percentage of mature insulin production and c peptide in insulin producing stem cells in response to different concentrations of glucose.

    Time frame: 1 year

  3. Insulin producing mesenchymal stem cells efficacy in insulin production in vivo

    Participants glycemic control will be assesed before and after insulin producing stem cells injection.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Children Hospital Eldemerdash
    Cairo, Egypt
    Recruiting
08

References and documents

Publications

  • Abou Zaki R, El-Osta A. Advancing type 1 diabetes therapy: autologous islet transplant breakthrough. Signal Transduct Target Ther. 2024 Dec 23;9(1):366. doi: 10.1038/s41392-024-02090-x. No abstract available. PubMed 39710778 ↗
  • Ulyanova O, Askarov M, Kozina L, Karibekov T, Shaimardanova G, Zhakupova A, Danilova D, Serebrennikova D. Autologous Mesenchymal Stem Cell Transplant in Patients with Type 1 Diabetes Mellitus. Exp Clin Transplant. 2019 Jan;17(Suppl 1):236-238. doi: 10.6002/ect.MESOT2018.P100. PubMed 30777564 ↗
  • Jayasinghe M, Prathiraja O, Perera PB, Jena R, Silva MS, Weerawarna PSH, Singhal M, Kayani AMA, Karnakoti S, Jain S. The Role of Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes. Cureus. 2022 Jul 27;14(7):e27337. doi: 10.7759/cureus.27337. eCollection 2022 Jul. PubMed 36042996 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2026, 13 months after the start.

Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 30, 2025
StartActual
Apr 1, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06951074
Responsible party
Sponsor
First posted
Apr 30, 2025
Start date
Apr 1, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Apr 30, 2025

Study contacts

Rasha S Elmetwally, MD
Contact
dr.rashaeladawy@med.asu.edu.eg
20201092143033 ext. 02
Rasha S Eladawy, MD
Contact
Rashaeladawy1@gmail.com
01092143033 ext. 02
Rasha S Elmetwally, A. Prof
principal investigator · Assistant professor of Pediatrics, Faculty of Medicine, Ain Shams University
Randa M Matter, Prof
study director · Professor of pediatrics, Faculty of Medicine, Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion